Medicare has announced 15 new drugs up for price negotiations, set to begin in the next several months with top drugmakers, ...
Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost more weight than those on a lower dose without experiencing an increase in side-effects, according to a ...
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...
39m
Accounting for around one-quarter of Europe's market cap, the GRANOLAS members are: GSK (GSK) (UK:GSK), Roche (CH:ROG), ASML (ASML) (NL:ASML), Nestlé (CH:NESN) (NSRGY), Novartis (NVS) (CH:NOVN), Novo ...
Drugmakers will have until the end of February to decide whether they want to participate in the second round of Medicare ...
The U.S. government targets 15 high-cost medications for Medicare price negotiations for 2027, under the Inflation Reduction ...
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...
The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a ...
Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.
In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...
It’s taken LVMH nearly a year-and-a-half to regain its spot as Europe’s biggest stock from Novo Nordisk A/S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback